Biogen (NASDAQ: BIIB) posted first-quarter results that beat the Wall Street consensus forecast, with the company raising its 2021 earnings guidance. However, Biogen’s outlook for the rest of the year largely hinges on FDA decisions regarding its pipeline drugs aducanumab and zuranolone. The Cambridge, Mass.-based biotech earned $410 million, or $2.69 per share, off sales…